Regen BioPharma, Inc.’s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
The company is rapidly expanding the number of activating compounds in its portfolio
SAN DIEGO, January 17, 2018 /PRNewswire/ — Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company’s contract research organization.
“We recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds,” says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. “In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element.”
“This additional information supports our prior work in this area and gives us confidence we are indeed on the right path,” says David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. “I am delighted that the agonist program is moving ahead in such a positive manner.”
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient’s own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Regen BioPharma, Inc.